- Available:In stock863
- Availability date:2020-07-30
- Dosage form:Bottle
- In stock:863 Items
Pharmacokinetics substances contained in liquid extracts of both plantain and thyme (thyme), including essential oils, as expectorants affect the properties, formation and transport of bronchial secretions.
Both indirect reflex action through the mucous membrane of the stomach and the direct effect of essential oils on the bronchial glands are carried out, enhancing their activity. This helps to increase, dilute and dissolve the bronchial secretion, as well as enhance the transport of secretion through the ciliary epithelium. This is especially important in the later stages of acute bronchitis and in chronic bronchitis, when there is increased secretion of viscous mucus by the submucous glands. In addition, essential oils, due to their surface activity, reduce the binding ability of highly viscous mucus on the mucous membrane of the trachea and bronchi.
Thyme is characterized by a pronounced antimicrobial potential of thymol and carvacrol. Plantain mucous substances of plantain help protect the damaged mucous membrane of the bronchi from further irritation.
Pharmacodynamics Not investigated.
Symptomatic treatment for inflammatory diseases of the respiratory tract. expectorant for the symptomatic treatment of productive cough. supporting agent for whooping cough.
Children aged 4 to 6 years are prescribed 1 teaspoon (5 ml) 3-5 times a day. children aged 6 to 12 years - 1 dessert spoon (10 ml) 3-5 times a day. children from 12 years of age and adults are prescribed 1-2 dessert spoons (10-20 ml) 3-5 times a day.
The duration of treatment is determined by the doctor individually, it depends on the course of the disease and the patient’s health status.
Hypersensitivity to the components of the drug, fructose intolerance; hypersensitivity to alkyl 4-hydroxybenzoate. hypersensitivity to plants of the family Labiaceae (lamiaceae), celery and pollen of birch (possible cross-reaction).
Gastroesophageal reflux disease, including reflux esophagitis, gastritis with increased acidity of gastric juice, stomach and duodenal ulcer, severe liver or kidney disease.
Gastrointestinal upsets (including nausea, vomiting, diarrhea), hypersensitivity reactions, including rash, urticaria, pruritus, angioedema, shortness of breath, exanthema are possible.
Before use, shake the syrup in a vial. the presence of plant-based components in the preparation may cause clouding of the syrup, however, the therapeutic effectiveness of the drug does not decrease from this.
The preparation Eucabal syrup contains 6.5 vol.% Ethanol, which creates a risk for patients with epilepsy, chronic alcoholism, liver diseases, organic brain diseases.
Do not use in patients with fructose intolerance, malabsorption of glucose-galactose or sucrose-isomaltose. Due to the sugar content it can be harmful to the teeth (tooth decay).
At the first signs of reactions caused by excessive sensitivity, the use of the drug should not be continued.
Use with caution in patients with diabetes. Eucabal syrup contains glucose, fructose and sucrose with a total sugar content in terms of sucrose of 0.6 g / ml. Thus, 1 teaspoon (5 ml) contains 3 g of sucrose or 0.25 bread units, and 1 dessert spoon (10 ml) contains 6 g of sucrose or 0.5 bread units.
Do not use simultaneously with antitussive drugs and drugs that reduce sputum production. due to the ethanol content (6.5 vol.%), there is the possibility of deterioration or increased effect of other drugs.
Symptomswith an overdose, nausea may appear, accompanied by a cough.
Treatment. Drug withdrawal. Therapy is symptomatic.
In a dark place at temperatures up to 25 ° C.